Vimarsana
Biggest News Aggregation in the World

Exercise Tolerance News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exercise Tolerance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exercise Tolerance Today - Breaking & Trending Today

CNN CNN This Morning July 6, 2024 - Vimarsana News

CNN CNN This Morning July 6, 2024

in the forecast. here in new york city, minus seven degrees. that is not a typo. the wind chill could reach minus 100 degrees on top of mt. washington in new hampshire because of the hurricane-force winds. the arctic blast in the northeast comes after a deadly ice storm reeked havoc across the south leaving eight people dead. we'll check in on the latest forecast in a moment. first, we have our cnn affiliate reporter live on the ground in burlington, vermont. it's close to zero degrees where you are. how are officials in the area bracing for this? how bad are we expecting it to get? ...

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 - Vimarsana News

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International...

Tenax Reports Publication of Phase 2 HELP Study to Evaluate Patients with Pulmonary Hypertension and Heart Failure | Tenax Reports Publication of Phase 2 HELP Study to Evaluate Patients with Pulmonary Hypertension and Heart FailureFinancial Buzz - Vimarsana News

Tenax Reports Publication of Phase 2 HELP Study to Evaluate Patients with Pulmonary Hypertension and Heart Failure | Tenax Reports Publication of Phase 2 HELP Study to Evaluate Patients with Pulmonary Hypertension and Heart FailureFinancial Buzz

25 Tenax Therapeutics, Inc. (NASDAQ: TENX)announced positive data from its Phase 2 HELP Study that evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.  Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial was published in the Journal of American College of Cardiology: Heart Failure. The publication had a 84% responder rate during the open label phase as 37 or 44 patients met responder criteria and were randomized to levosimendan (n=18) or ...